Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

Also called NCT05300672

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 207 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05300672
  • EudraCT 2020-005242-41
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05300672. Randomized; no masking; primary purpose treatment. Start 2022-02-08 (actual); primary completion 2024-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)
Acronym
FibER
Condition
Intracranial Hemorrhages
Intervention (Drug)
fibrinogen infusion
Lead sponsor
Azienda Usl di Bologna (class: other government)
Collaborator
Ministero della Salute, Italy (class: other)

Record details

Record id
cardio:ct-nct05300672
Content hash
c9ac5fd90761cfd8137214b20330a657b69fbd34dd8cb25337fddba34f30f80c